Astrazeneca (AZN) EV to EBITDA (2009 - 2026)

Astrazeneca has reported EV to EBITDA for 18 years, with the latest figure at 91.24 in Q2 2026.

• On a quarterly basis, EV to EBITDA rose 53.04% year-over-year to 91.24 in Q2 2026; TTM through Jun 2026 was 20.66, a 11.88% increase from a year earlier, with the FY2025 full-year figure at 20.29, up 2.74% from the prior year.
• EV to EBITDA was 91.24 for Q2 2026 at Astrazeneca, up from 70.14 in the prior quarter.
• The five-year high for EV to EBITDA was 370.74 in Q2 2022, with the low at 28.5 in Q4 2023.
• Average EV to EBITDA over 5 years is 106.07, with a median of 86.64 recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EV to EBITDA jumped 251.27% in 2022, then sank 76.3% in 2023.
• Over 5 years, EV to EBITDA stood at 76.55 in 2022, then sank by 62.77% to 28.5 in 2023, then surged by 240.43% to 97.02 in 2024, then retreated by 3.49% to 93.63 in 2025, then slipped by 2.55% to 91.24 in 2026.
• The last three EV to EBITDA figures came in at 91.24 (Q2 2026), 70.14 (Q1 2026), and 93.63 (Q4 2025), per Business Quant data.